{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["145(17)"],"submitter":["Mantzaris I"],"pubmed_abstract":["<h4>Abstract</h4>Venetoclax (Ven), when combined with intensive chemotherapy, shows promise for untreated acute myeloid leukemia (AML), but its integration with the 7+3 regimen remains underexplored. In a phase 1b study, we assessed the safety and efficacy of Ven with daunorubicin and cytarabine in patients with newly diagnosed AML. A total of 34 patients (median age, 59 years; 62% non-White) received Ven at escalating durations (8, 11, or 14 days). Adverse events included febrile neutropenia (100%), sepsis (29%), and enterocolitis (23.5%), but there were no induction deaths. The median recovery times for neutrophils (>1.0 × 103/μL) and platelets (>100 × 103/μL) were less than 30 days. Composite complete remission was achieved in 85.3% of patients, and 86.2% were negative for measurable re"],"journal":["Blood"],"pagination":["1870-1875"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12060153"],"repository":["biostudies-literature"],"pubmed_title":["Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study."],"pmcid":["PMC12060153"],"pubmed_authors":["Kornblum NS","Shah L","Verceles JA","Tirone B","Shah N","Fehn K","Mantzaris I","Sica RA","Shapiro L","Goldfinger M","Kim M","Feldman EJ","Cooper DL","Dhawan A","Uriel M","Verma A","Konopleva M","Shastri A","Gritsman K","Munoz A","Zhang C","Chambers N","Clark S"],"additional_accession":[]},"is_claimable":false,"name":"Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study.","description":"<h4>Abstract</h4>Venetoclax (Ven), when combined with intensive chemotherapy, shows promise for untreated acute myeloid leukemia (AML), but its integration with the 7+3 regimen remains underexplored. In a phase 1b study, we assessed the safety and efficacy of Ven with daunorubicin and cytarabine in patients with newly diagnosed AML. A total of 34 patients (median age, 59 years; 62% non-White) received Ven at escalating durations (8, 11, or 14 days). Adverse events included febrile neutropenia (100%), sepsis (29%), and enterocolitis (23.5%), but there were no induction deaths. The median recovery times for neutrophils (>1.0 × 103/μL) and platelets (>100 × 103/μL) were less than 30 days. Composite complete remission was achieved in 85.3% of patients, and 86.2% were negative for measurable re","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-01T05:58:44.177Z","creation":"2026-04-08T09:46:48.203Z"},"accession":"S-EPMC12060153","cross_references":{"pubmed":["39919267"],"doi":["10.1182/blood.2024026700"]}}